Non-Hodgkin lymphoma (NHL) comprises more than 60 biologically distinct malignancies, yet the greatest opportunity to improve outcomes often occurs before subtype-specific treatment begins. From the AAVBC's perspective, value-based care starts with accountable diagnostic stewardship: persistent unexplained lymphadenopathy, or chronic gastrointestinal, cutaneous, neurologic, or other treatment-refractory presentations that could represent extranodal lymphoma, should prompt an urgent lymphoma pathway rather than repeated empiric therapy or prolonged observation. Any persistent firm, rubbery, non-tender lymph node should raise suspicion, with excisional lymph node biopsy—not fine-needle aspiration—requested whenever feasible. The highest-value primary care intervention is shortening the time from suspicion to definitive diagnosis.
Drawing from current NCCN guidance, AAVBC's Non-Hodgkin's Lymphoma Quick Reference Guide focuses on the clinical decisions where primary care creates the greatest value. It highlights ICD-10 subtype coding, HCC/RAF mapping, Lugano staging, prognostic indices, MEAT documentation, and recognition of extranodal disease patterns that commonly delay diagnosis. Beyond referral, the guide emphasizes the PCP's role as an accountable co-manager—preventing febrile neutropenia, tumor lysis syndrome, steroid-induced hyperglycemia, polypharmacy toxicity, and avoidable emergency visits while coordinating survivorship care. It also reinforces geriatric-informed management, recognizing that treatment intensity should be guided by lymphoma subtype and functional reserve rather than chronological age alone, supporting better outcomes and more efficient resource utilization.
AAVBC’s Deep-Dive series offers a comprehensive, structured analysis of Non-Hodgkin's lymphoma — moving far beyond quick-reference essentials. These guides provide an integrated review of epidemiology, diagnostic strategy, staging, coding logic, MEAT-aligned documentation examples, treatment guidelines, review vulnerabilities, and cost-utilization considerations. The Deep-Dive combines evidence-informed clinical guidance with practical operational tools to support a deeper understanding of disease complexity and provide multidisciplinary teams with strategies to thrive within value-based frameworks.
Non-Hodgkin lymphoma (NHL) comprises more than 60 biologically distinct malignancies, yet the greatest opportunity to improve outcomes often occurs before subtype-specific treatment begins. From the AAVBC's perspective, value-based care starts with accountable diagnostic stewardship: persistent unexplained lymphadenopathy, or chronic gastrointestinal, cutaneous, neurologic, or other treatment-refractory presentations that could represent extranodal lymphoma, should prompt an urgent lymphoma pathway rather than repeated empiric therapy or prolonged observation. Any persistent firm, rubbery, non-tender lymph node should raise suspicion, with excisional lymph node biopsy—not fine-needle aspiration—requested whenever feasible. The highest-value primary care intervention is shortening the time from suspicion to definitive diagnosis.
Drawing from current NCCN guidance, AAVBC's Non-Hodgkin's Lymphoma Quick Reference Guide focuses on the clinical decisions where primary care creates the greatest value. It highlights ICD-10 subtype coding, HCC/RAF mapping, Lugano staging, prognostic indices, MEAT documentation, and recognition of extranodal disease patterns that commonly delay diagnosis. Beyond referral, the guide emphasizes the PCP's role as an accountable co-manager—preventing febrile neutropenia, tumor lysis syndrome, steroid-induced hyperglycemia, polypharmacy toxicity, and avoidable emergency visits while coordinating survivorship care. It also reinforces geriatric-informed management, recognizing that treatment intensity should be guided by lymphoma subtype and functional reserve rather than chronological age alone, supporting better outcomes and more efficient resource utilization.
AAVBC’s Deep-Dive series offers a comprehensive, structured analysis of Non-Hodgkin's lymphoma — moving far beyond quick-reference essentials. These guides provide an integrated review of epidemiology, diagnostic strategy, staging, coding logic, MEAT-aligned documentation examples, treatment guidelines, review vulnerabilities, and cost-utilization considerations. The Deep-Dive combines evidence-informed clinical guidance with practical operational tools to support a deeper understanding of disease complexity and provide multidisciplinary teams with strategies to thrive within value-based frameworks.
